Amgen Inc. $AMGN Shares Acquired by QRG Capital Management Inc.

Posted by Geri Gentry on Sep 23rd, 2026

QRG Capital Management Inc. lifted its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 14.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 107,906 shares of the medical research company’s stock after acquiring an additional 13,523 shares during the period. QRG Capital Management Inc.’s holdings in Amgen were worth $36,197,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently added to or reduced their stakes in AMGN. Wellington Altus USA Inc. lifted its holdings in Amgen by 72.3% in the 2nd quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 34 shares in the last quarter. Tower View Wealth Management LLC grew its holdings in shares of Amgen by 331.6% during the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock worth $29,000 after buying an additional 63 shares in the last quarter. Security National Bank of Sioux City Iowa IA purchased a new stake in shares of Amgen during the second quarter worth $36,000. Evergreen Advisors LLC acquired a new stake in shares of Amgen in the first quarter valued at about $37,000. Finally, University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Amgen in the fourth quarter valued at about $44,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on AMGN shares. UBS Group restated a “buy” rating and set a $430.00 price target on shares of Amgen in a research report on Thursday, September 17th. TD Cowen increased their price objective on shares of Amgen from $420.00 to $452.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Robert W. Baird raised their target price on shares of Amgen from $215.00 to $230.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 5th. Sanford C. Bernstein boosted their target price on Amgen from $335.00 to $345.00 and gave the stock a “market perform” rating in a report on Thursday, August 6th. Finally, Jefferies Financial Group restated a “hold” rating and issued a $410.00 target price on shares of Amgen in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $383.46.

View Our Latest Research Report on Amgen

Amgen Trading Down 1.0%

AMGN stock traded down $4.15 during midday trading on Wednesday, hitting $406.09. 2,814,707 shares of the company’s stock were exchanged, compared to its average volume of 2,757,001. Amgen Inc. has a 1-year low of $269.77 and a 1-year high of $447.03. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. The stock has a market capitalization of $219.54 billion, a PE ratio of 25.24, a P/E/G ratio of 2.84 and a beta of 0.43. The business has a 50-day simple moving average of $403.52 and a two-hundred day simple moving average of $368.01.

Amgen (NASDAQ:AMGN – Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating the consensus estimate of $5.62 by $0.67. The business had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The company’s quarterly revenue was up 9.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, sell-side analysts predict that Amgen Inc. will post 22.94 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were given a $2.52 dividend. The ex-dividend date of this dividend was Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a yield of 2.5%. Amgen’s dividend payout ratio is presently 62.65%.

Key Amgen News

Here are the key news stories impacting Amgen this week:

Positive Sentiment: Amgen reported positive topline results from the Phase 3 OASIZ 301 trial. Dazodalibep achieved a statistically significant and clinically meaningful improvement in the primary endpoint—change in disease activity from baseline at week 48—in adults with moderate-to-severe systemic Sjögren’s disease. Amgen’s autoimmune drug succeeds in late-stage trial
Positive Sentiment: The results raised hopes that dazodalibep could become an important new autoimmune-disease product, potentially expanding Amgen’s long-term revenue base. Reports said the treatment showed sustained improvement through week 48. AMGN’s Dazodalibep Meets Goal in Systemic Sjogren’s Disease Study
Positive Sentiment: Jefferies raised its Amgen price target to $410 from $367 following the data, while Goldman Sachs maintained a Buy rating and $450 target. The favorable views reinforce the perception that Amgen’s pipeline may support further upside. Amgen price target raised by Jefferies
Neutral Sentiment: Amgen’s shares have recently traded near the $406 level, above the 50-day moving average of $403.52 and well above the 200-day average of $368.01, indicating strong longer-term momentum but also a relatively elevated valuation.
Negative Sentiment: Bank of America kept an Underperform rating and $317 price target, citing uncertainty around the dazodalibep data. Citi also flagged open questions, while approval filing is expected to depend on results from another trial. Amgen Underperform Maintained
Negative Sentiment: Erste Group slightly reduced its FY2027 earnings estimate to $24.36 per share from $24.43, underscoring that near-term earnings expectations have not materially improved despite the pipeline news.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy Grygiel sold 2,970 shares of the stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the transaction, the senior vice president owned 7,340 shares of the company’s stock, valued at $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Rachna Khosla sold 2,000 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00. Following the transaction, the senior vice president directly owned 6,404 shares of the company’s stock, valued at approximately $2,642,098.28. This trade represents a 23.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 6,222 shares of company stock worth $2,540,926 in the last ninety days. 0.85% of the stock is currently owned by corporate insiders.

About Amgen

(Free Report)

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and rare diseases. The company uses biologic research, genetics and other advanced technologies to develop treatments intended to address significant unmet medical needs.

Amgen’s medicines include Enbrel for certain inflammatory diseases; Prolia and Evenity for bone-related conditions; Xgeva for complications associated with cancer and bone disease; Repatha for cardiovascular risk reduction; Otezla for inflammatory conditions; and Aimovig for migraine prevention.